Astaxanthin Shields Skeletal Muscle from Fat-Diet Damage via Mitochondrial Boost

Skeletal muscle is acutely vulnerable to the metabolic havoc wrought by high-fat diets. Excessive lipid accumulation in muscle fibers triggers insulin resistance, inflammatory signaling, and mitochondrial fragmentation—ultimately eroding muscle strength and endurance. Because mitochondria sit at the center of both energy production and oxidative stress regulation, boosting mitochondrial biogenesis has emerged as a therapeutic target worth pursuing in obesity-related muscle disease.

This study systematically tested whether astaxanthin (Asta), a potent marine-derived carotenoid antioxidant, could protect skeletal muscle under metabolic stress. Male C57BL/6J mice were placed on a 60%-fat HFD for 18 weeks; from week 6 onward, half received oral Asta (200 mg/kg, every other day) for 12 weeks. Parallel in vitro experiments exposed differentiated C2C12 myotubes to palmitate (PA, 0–300 µM) for 36 hours, with Asta (150 µM) added for the final 24 hours.

Notably, Asta did not alter body weight or circulating cholesterol, triglycerides, LDL-C, HDL-C, or glucose in HFD-fed mice—suggesting its benefits are downstream of systemic lipid handling. Yet histological analysis (H&E, PAS, Oil Red O staining) showed markedly reduced muscle fiber atrophy, preserved glycogen content, and lower intramuscular lipid droplets in Asta-treated HFD mice. Behavioral testing confirmed functional gains: grip strength, rotarod latency, and open-field locomotion were all significantly improved versus untreated HFD controls. Transmission electron microscopy revealed that Asta preserved mitochondrial ultrastructure, reducing the swelling and cristae disorganization typical of HFD-induced mitochondrial damage.

At the molecular level, Asta upregulated mitochondrial biogenesis proteins (including PGC-1α pathway components), suppressed pro-fission dynamics, increased antioxidant enzyme activity (SOD, CAT), reduced lipid peroxidation markers (MDA), and elevated ATP production—effects replicated in PA-stressed C2C12 cells. Inflammatory gene expression was also attenuated in both models. Collectively, these data paint a coherent mechanistic picture: Asta intercepts the HFD-driven vicious cycle in which excess lipids generate ROS, ROS damage mitochondria, and damaged mitochondria further amplify oxidative stress and inflammation.

The implications extend beyond obesity research. Mitochondrial decline in skeletal muscle is a hallmark of aging (sarcopenia) and metabolic disease, and compounds that safely enhance mitochondrial biogenesis without systemic lipid-lowering side effects are clinically desirable. Astaxanthin's excellent safety profile and oral bioavailability make it a candidate worth pursuing in human trials targeting muscle preservation under conditions of metabolic or aging-related stress. Limitations include the exclusive use of male mice, the absence of mechanistic inhibitor experiments to confirm pathway specificity, and doses (200 mg/kg in mice) that may not translate directly to practical human supplementation levels.